Oliver Sartor, MD

A look toward the future development of bispecific T-cell engages (BiTEs) and CAR T-cell therapy for metastatic castration-resistant prostate cancer (mCRPC).

A review of the PSMA-targeted radioligand therapies that are currently in development.

Oliver Sartor, MD, reviews clinical data from the TheraP trial looking at the activity of 177Lu-PSMA617 in patients with metastatic castration-resistant prostate cancer.

Key opinion leaders expand on the broad clinical utility of prostate-specific membrane antigen (PSMA) for patients with advanced prostate cancer.

Oliver Sartor, MD, and Ulka Vaishampayan, MD, discuss noninvasive imaging with PSMA PET/CT for patients with advanced prostate cancer.

Oliver Sartor, MD, discusses the use of phenotypic biomarkers such as prostate-specific membrane antigen (PSMA), and how these biomarkers can be utilized for prediction of prognosis as well as responsiveness to therapy.

Practical considerations for the timing of genomic testing throughout lines of therapy for patients with advanced prostate cancer.

Ulka N. Vaishampayan, MD, discusses somatic and germline genetic testing for patients with advanced prostate cancer.

Oliver Sartor, MD, reviews the treatment approaches that are currently available for patients with metastatic castration-resistant prostate cancer (mCRPC).

Experts in genitourinary oncology specializing in advanced prostate cancer discuss the evolution of personalized approaches for patients with metastatic castration-resistant prostate cancer (mCRPC).

Experts in genitourinary oncology discuss emerging research surrounding the clinical utility of phenotypic biomarkers, such as prostate-specific membrane antigen (PSMA), for use in the treatment of metastatic castration-resistant prostate cancer.

A. Oliver Sartor, MD, Medical Director of Tulane Cancer Center, explains why primary care physicians and oncologists/urologists have differences of opinion when it comes to prostate-specific antigen (PSA) testing.

Oliver Sartor, MD, medical director, Tulane Cancer Center, discusses how radium-223 dichloride became deemed safe in patients with bone-metastatic castration-resistant prostate cancer (CRPC). The treatment was tested in an open-label phase I/II trial where patients were given 6 additional doses of radium-223 on top of their original 6-dose regimen.

Sartor says the test would lay out molecular data regarding a patient's malignancy and allow community oncologists to determine what would be the best course of treatment. He added that the hope for this study is to replace the "trial and error" method of treatment with something more concrete.

Oliver Sartor, MD, medical director, Tulane Cancer Center, discusses the United States experience of the Expanded Access Program (EAP) on radium-223 for prostate cancer.

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses a trial that would study Provenge (sipuleucel-T) in combination with radium-223 as a potential treatment option for patients with prostate cancer.

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses a phase III trial of custirsen (OGX-011) and its potential for treatment in patients with prostate cancer.

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses PSA testing guidelines.